

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
16 January 2025 (16.01.2025)



(10) International Publication Number
WO 2025/011450 A1

(51) International Patent Classification:

C07D 401/04 (2006.01) A61K 31/415 (2006.01)
C07D 257/04 (2006.01) A61K 31/4164 (2006.01)
C07D 249/02 (2006.01) A61K 31/4192 (2006.01)
C07D 249/04 (2006.01) A61K 31/4196 (2006.01)
C07D 249/08 (2006.01) A61P 9/04 (2006.01)
C07D 233/00 (2006.01) A61P 9/06 (2006.01)
C07D 231/02 (2006.01) A61P 9/08 (2006.01)
A61K 31/41 (2006.01) A61P 9/10 (2006.01)

(21) International Application Number:

PCT/CN2024/103810

(22) International Filing Date:

05 July 2024 (05.07.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2023/106400

07 July 2023 (07.07.2023)

CN

(71) Applicant: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35,
4056 Basel (CH).

(72) Inventor; and

(71) Applicant (for SC only): **TANG, Haihao** [CN/CN]; China
Novartis Institute For Biomedical Research Co., Ltd.,
B3-5F, 4218 Jinke Road, Zhangjiang Hi-tech Park, Pudong
New Area, Shanghai 201203 (CN).

(72) Inventors: **DAY, Robert Francis**; Novartis Institutes For
BioMedical Research, Inc., 250 Massachusetts Avenue,
Cambridge, MA 02139 (US). **FRIEDMAN, Adam**; No-
vartis Institutes For BioMedical Research, Inc., 250 Massa-
chusetts Avenue, Cambridge, MA 02139 (US). **GULGEZE**
EFTHYMIU, Hatice Belgin; Novartis Institutes For Bio-
Medical Research, Inc., 250 Massachusetts Avenue, Cam-
bridge, MA 02139 (US). **HARRISON, Tyler**; Chinook
Therapeutics, A Novartis Company, 887 Great Northern
Way #210, Vancouver, BC, V5T 4T5 (CA). **KING, Sandra**
Marie; Novartis Institutes For BioMedical Research, Inc.,
250 Massachusetts Avenue, Cambridge, MA 02139 (US).
LARROW, Jay Francis; Novartis Institutes For BioMed-
ical Research, Inc., 250 Massachusetts Avenue, Cambridge,
MA 02139 (US). **LAU, Sii Hong**; Novartis Institutes For
BioMedical Research, Inc., 250 Massachusetts Avenue,
Cambridge, MA 02139 (US). **PATEL, Tajesh**; Novartis
Institutes For BioMedical Research, Inc., 250 Massachu-
setts Avenue, Cambridge, MA 02139 (US). **PENG, Yun-**
shan; Novartis Institutes For BioMedical Research, Inc.,
250 Massachusetts Avenue, Cambridge, MA 02139 (US).
SMITH, Nichola; 16 Sparhawk Drive, Burlington, Massa-

chusetts 01803 (US). **WU, Yanxiang**; China Novartis Insti-
tute For Biomedical Research Co., Ltd., B3-5F, 4218 Jinke
Road, Zhangjiang Hi-tech Park, Pudong New Area, Shang-
hai 201203 (CN).

(74) Agent: **ZHONGZI LAW OFFICE**; 7F, New Era Building,
26 Pinganli Xidajie, Xicheng District, Beijing 100034 (CN).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: SODIUM CHANNEL BLOCKERS

(57) Abstract: The present disclosure relates to sulfonamide compounds, the use thereof for modulat-ing the sodium channel Nav1.5
and methods of treating or preventing diseases, disorders, or conditions using the same.

WO 2025/011450 A1